Skip to content

Quality of Life in Moderate-to-Severe Obstructive Sleep Apnea: Pre- vs. Post-Surgery

Quality of Life in Moderate-to-Severe Obstructive Sleep Apnea: Pre- vs. Post-Surgery

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500102351
Enrollment
Unknown
Registered
2025-05-13
Start date
2025-05-15
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea

Interventions

Moderate-to-Severe OSA Group:None

Sponsors

Affiliated Zhongshan Hospital of Dalian University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Meet the criteria for moderate to severe OSA diagnosis revised by the General Practice Branch of the Chinese Medical Association in the "2018 Guideline for Primary Diagnosis and Treatment of Adult Obstructive Sleep Apnea," with an AHI of >= 15 events/hour in PSG. 2.Age between 18-65 years, and subjects must have undergone UPPP surgery between 2023-2024. 3.Preoperative monitoring with VNG and PSG was conducted. 4.Subjects should have quality of life assessment data including the Dizziness Handicap Inventory (DHI), Tinnitus Handicap Inventory (THI), Pittsburgh Sleep Quality Index (PSQI), and Epworth Sleepiness Scale (ESS) before and after surgery. 5.No history of past ear trauma or surgery, otitis media, hearing loss, tinnitus, no history of exposure to ototoxic medications or noise. 6.Agree to participate in this study.

Exclusion criteria

Exclusion criteria: 1.Patients with peripheral vertigo diseases such as vestibular neuritis, benign paroxysmal positional vertigo (BPPV), and acoustic neuroma, as well as central vertigo diseases such as cerebral hemorrhage, migraine, and brain tumors. 2.Patients with severe hypertension, coronary heart disease, diabetes, hyperlipidemia, and other cardiovascular, endocrine-metabolic, and psychiatric diseases. 3.Patients taking medications that affect sleep during the treatment period.

Design outcomes

Primary

MeasureTime frame
Dizziness Handicap Inventory score;Tinnitus Handicap Inventory score;Pittsburgh Sleep Quality Index score;Epworth Sleepiness Scale score;

Secondary

MeasureTime frame
Videonystagmography;polysomnography;

Countries

China

Contacts

Public ContactNa Hua

Affiliated Zhongshan Hospital of Dalian University

huanaship@163.com+86 13889481076

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026